Nucleai vs Valar Labs (2026)
Both extract a prediction from tissue and they demand very different things from the laboratory. Nucleai does spatial biology, integrating high plex proteomics with histopathology and clinical data to find biomarkers in how cells are arranged, which is where immunotherapy response signal has repeatedly been found, and it requires specialised multiplex staining most clinical laboratories do not run. Valar predicts treatment response and prognosis from the ordinary stained slide the laboratory already produces, deepest in non muscle invasive bladder cancer, with multi centre validation across four continents behind it. For a pharmaceutical stratification programme, Nucleai measures the thing being asked about. For a clinical service wanting a prognostic answer next week without new assays, Valar needs nothing you do not already have.
- Spatial biology is the measurement, integrating high plex proteomics with histopathology and clinical data to find predictive spatial biomarkers rather than counting or classifying cells.
- It detects spatial relationships human readers cannot practically assess, with named pharmaceutical partnerships supporting the research side of that claim.
- For immunotherapy response stratification, where cells sit relative to each other has repeatedly been where the signal is.
- It predicts treatment response and prognosis from the standard stained slide a laboratory already produces, with no additional assay or tissue required.
- The evidence base is the strongest among the prognostic pathology vendors here, including multi centre validation across an international cohort spanning four continents.
- Depth in non muscle invasive bladder cancer is real, with two products addressing different decisions in that pathway.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Nucleai and Valar Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Nucleai | Valar Labs |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2016 | 2021 |
| Headquarters | Tel Aviv, Israel | Palo Alto, California, United States |
| Website | nucleai.ai | valarlabs.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Nucleai its top capability grade on AI Centrality. Set against Valar Labs, Nucleai does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Valar Labs its top capability grade on AI Centrality, Clinical and Operational Evidence and HIPAA and BAA Posture. Set against Nucleai, Valar Labs grades higher on several axes, including Clinical and Operational Evidence, HIPAA and BAA Posture and Deployment Model and Data Residency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Nucleai or Valar Labs?
The AI Health Index grades Valar Labs higher than Nucleai on every axis that separates them, several axes, including Clinical and Operational Evidence, HIPAA and BAA Posture and Deployment Model and Data Residency. Nucleai does not grade higher on any scored axis.
Where do Nucleai and Valar Labs differ most?
The widest separation the AI Health Index records between Nucleai and Valar Labs is on HIPAA and BAA Posture, where Nucleai grades C and Valar Labs grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Nucleai and Valar Labs grade the same?
The AI Health Index grades Nucleai and Valar Labs the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Nucleai and Valar Labs not disclosed?
At the last review, at least one of Nucleai and Valar Labs published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
The input requirements differ sharply and that is the practical constraint: multiplex spatial proteomics requires specialised staining and imaging that most clinical laboratories do not run, while a prognostic model on a routine stained slide requires nothing new. Both are research grade or laboratory developed rather than cleared devices, so no regulator has reviewed either performance claim, and the validation cohorts are what a buyer should interrogate. Nucleai publishes no health privacy or data governance framework despite processing biopsy images correlated with clinical data. Neither publishes pricing.